{
  "compound": "Cannabidiol (Epidiolex)",
  "condition": "EPILEPSY",
  "effect_size": "Large (21-22% vs placebo)",
  "study_type": "RCT",
  "source": "NORML:EPILEPSY_RCT_003",
  "participants": "224 patients with TSC-associated seizures",
  "year": 2021,
  "notes": "Epidiolex for Tuberous Sclerosis Complex: Phase 3 (GWPCARE6)",
  "confidence": "medium",
  "abstract": "25mg CBD: 48.6% reduction; 50mg CBD: 47.5% reduction; Placebo: 26.5% (p<0.001); Third FDA indication"
}